AGENDA
8:00-9:00 a.m. Breakfast Keynote
Calaneet Balas, President & CEO, ALS Association
Calaneet will share how advocacy and outreach at the Association has propelled research funding and awareness for ALS.

9:15-10:15 a.m. Discussion Session: Value Based Partnerships and Pricing Innovation
How do key healthcare stakeholders successfully agree on pricing innovation?
Panelists: Peter Juhn, MD, MPH, VP and Global Head of Value Based Partnerships, Amgen
William Bishop VP, Consultant and Employer Strategies, HCA

10:15-10:45 a.m. Networking Coffee Break & C Level Unplugged in Exhibit Hall
C Level Unplugged Featuring: Jason Myers, Co-Founder and CEO, ArcherDX

10:45-11:45 a.m. Discussion Session: Emergence of Artificial Intelligence
The adoption and integration of Artificial Intelligence (AI) and machine learning are poised to transform healthcare and has become one of the most significant technological advances recently. John Kelley, Chairman and CEO, CereScan
Paul Beresford, Chief Business Development Officer, Biodesix

Greg Dameron, Director of Engineering, Medtronic

12:00-1:00 p.m. Lunch Keynotes
Patricia L. Silverstein, President & Chief Economist, Development Research Partners
Dianne Primavera, Jared Polis Democratic Gubernatorial Nominee Running Mate
Lang Sias, Walker Stapleton Republican Gubernatorial Nominee Running Mate

1:00-1:30 p.m. Networking Coffee Break & C Level Unplugged in Exhibit Hall C Level Unplugged
Featuring: Gillian C. Ivers-Read, Executive VP and Chief Regulatory Officer, Clovis Oncology

1:30- 2:30 p.m. Discussion Session: Changing Behaviors
Learn how local pilot programs in healthcare systems, companies and innovative partnerships are modifying behaviors for the community, patients and physicians to provide safer alternatives and better outcomes.
Todd Evenson, COO, Medical Group Management Association
Heidi Wald, MD, MSPH, VP for Clinical Performance and Interim VP for Quality and Safety, SCL Health

Increasingly, BD’s from large companies have shown more interest in investing into companies that are strategically aligned with their portfolios.
Renee Compton Ryan, VP, Venture Investments, Johnson & Johnson Innovation
Yvonne Kobayashi, Ph.D., Senior Director, Emerging Technology and Innovation, Corporate Business Development, Eli Lily & Co.

Michael Coleman, Director Biologics Commercialization, Merck & Co.

John Chindlund, VP, Global Marketing & Medical Education, Zimmer Biomet

3:45-4:30 p.m. Venture Showcase
Three emerging Colorado life science companies pitch their technology to a panel of investors for the $7,500 Venture showcase cash prize.
Brava Diagnostics, Boulder, CO
Cetya Therapeutics, Ft. Collins, CO
Velóce Corporation, Ft. Collins, CO

4:30-5:00 p.m. Closing Keynote: The Future of Immunotherapy
Terry Fry, MD, Director of Cancer Immunotherapy, University of Colorado School of Medicine and Children’s Hospital Colorado